Cell reports. Medicine · 2025
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.
СтатьяКлиническое исследование I фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Monberg Tine J, Pakola Santeri A, Albieri Benedetta, Ellebaek Eva, Donia Marco, Eefsen Rikke L, Borch Troels H, Kudling Tatiana V, Lorentzen Torben, Hendel Helle W, Vestergaard Cecilie, Lorentzen Cathrine, Holmstroem Rikke B, Arias Victor, Khammari Amir, Kistler Claudia, Santos João M, Clubb James H A, Haybout Lyna, Westergaard Marie C W, Met Özcan, Quixabeira Dafne C A, Jirovec Elise, Havunen Riikka, Sorsa Suvi, Cervera-Carrascon Victor, Dreno Brigitte, Hemminki Akseli, Svane Inge Marie
Аннотация
Tumor-infiltrating lymphocytes (TILs) are effective in the treatment of metastatic melanoma (MM), but toxicity limits its application. TILT-123 (igrelimogene litadenorepvec) is an oncolytic adenovirus producing interleukin-2 (IL-2) and tumor necrosis factor (TNF) upon replication. In this phase 1 trial, 17 patients with metastatic checkpoint inhibitor-resistant melanoma are treated with TILT-123 and TILs without preconditioning chemotherapy or postconditioning IL-2. The treatment is safe and feasible. According to computed tomography (CT), the objective response rate is 11.7% (2/17) and disease control is observed in 35% (6/17), including a partial response lasting >8 months and a durable complete response in a mucosal melanoma patient. According to positron emission tomography (PET), disease control is observed in 7/15 (47%) with minor or partial responses in 4/15 (27%). In the initial TILT-123 monotherapy phase of the trial, disease control is observed in 6/17 (35%) and 10/16 (63%) in CT and PET, respectively. The study demonstrates good tolerability and preliminary efficacy.